Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome

Inclusion Criteria: * Mucopolysaccharidosis type VI (MPS VI, Maroteaux-Lamy syndrome) treated with a prior allogeneic transplant \>2 years previously * Persons currently receiving Naglazyme may be accepted into the study * Age \> 2 years * \>10% engrafted based on most recent testing * Willing to commit to traveling to the University of Minnesota every 6 months * Written informed consent with parent/guardian consent for children \< 18 years of age or persons unable to consent with minor assent if appropriate Exclusion Criteria: * History of cardiac or pulmonary insufficiency or those requiring continuous supplemental oxygen * Pregnant or breastfeeding * Any condition that, in the view of the investigator, places the patient at high risk of poor treatment compliance or of not completing the study